CSIR suggests cap on remdesivir price

The Council of Scientific and Industrial Research (CSIR) has suggested regulating price of the experimental Covid-19 medicine remdesivir used in hospitalised patients who are on oxygen support on the basis of a cost analysis of the API used in the formulation.


Post a Comment

0 Comments